Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study
Open Access
- 1 June 2017
- journal article
- research article
- Published by Taylor & Francis in International Journal of Chronic Obstructive Pulmonary Disease
- Vol. ume 12, 1731-1740
Abstract
Background: A previous Phase IIIb study (NCT01462929) in patients with moderate to severe COPD demonstrated that 6 weeks of treatment with aclidinium led to improvements in 24-hour bronchodilation comparable to those with tiotropium, and improvement of symptoms versus placebo. This post hoc analysis was performed to assess the effect of treatment in the symptomatic patient group participating in the study. Methods: Symptomatic patients (defined as those with Evaluating Respiratory Symptoms [E-RS™] in COPD baseline score ≥10 units) received aclidinium bromide 400 µg twice daily (BID), tiotropium 18 µg once daily (QD), or placebo, for 6 weeks. Lung function, COPD respiratory symptoms, and incidence of adverse events (AEs) were assessed. Results: In all, 277 symptomatic patients were included in this post hoc analysis. Aclidinium and tiotropium treatment improved forced expiratory volume in 1 second (FEV1) from baseline to week 6 at all time points over 24 hours versus placebo. In addition, improvements in FEV1 from baseline during the nighttime period were observed for aclidinium versus tiotropium on day 1 (aclidinium 157 mL, tiotropium 67 mL; PP1 from baseline versus placebo and tiotropium at day 1 (aclidinium 136 mL, tiotropium 68 mL; PP Conclusion: In this post hoc analysis of symptomatic patients with moderate to severe COPD, aclidinium 400 µg BID provided additional improvements compared with tiotropium 18 µg QD in: 1) bronchodilation, particularly during the nighttime, 2) daily COPD symptoms (E-RS), 3) early-morning and nighttime symptoms, and 4) early-morning limitation of activity.Keywords
This publication has 21 references indexed in Scilit:
- The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studiesRespiratory Research, 2016
- The global economic burden of asthma and chronic obstructive pulmonary diseaseThe International Journal of Tuberculosis and Lung Disease, 2016
- Improvements in patient-reported outcomes: A prospective, non-interventional study with aclidinium bromide for treatment of COPDRespiratory Medicine, 2015
- Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS studyRespiratory Research, 2014
- Measuring respiratory symptoms in clinical trials of COPD: reliability and validity of a daily diaryThorax, 2014
- Performance of the EXAcerbations of Chronic Pulmonary Disease Tool Patient-reported Outcome Measure in Three Clinical Trials of Chronic Obstructive Pulmonary DiseaseAnnals of the American Thoracic Society, 2014
- Efficacy and Safety of Aclidinium Bromide Compared with Placebo and Tiotropium in Patients with Moderate-to-Severe Chronic Obstructive Pulmonary Disease: Results from a 6-week, Randomized, Controlled Phase Iiib StudyCOPD: Journal of Chronic Obstructive Pulmonary Disease, 2013
- COPD symptoms in the morning: impact, evaluation and managementRespiratory Research, 2013
- Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPDChest, 2012
- Night-time symptoms: a forgotten dimension of COPDEuropean Respiratory Review, 2011